DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 5,614,399
|Title:||Plant ubiquitin promoter system|
|Abstract:||A method of inducibly enhancing the constitutive expression of a DNA sequence of interest is described in which plant cells are transformed with a DNA sequence of interest that is operably joined to a plant ubiquitin regulatory region comprised of a heat shock element, a promoter, a transcription start site, an intron, and a translation start site. When monocot or dicot plant cells are subjected to permissive heat shock temperatures, the level of expression of the DNA sequence of interest is enhanced.|
|Inventor(s):||Quail; Peter H. (Richmond, CA), Christensen; Alan H. (Albany, CA), Hershey; Howard P. (West Chester, PA), Sharrock; Robert A. (El Cerrito, CA), Sullivan; Thomas D. (Madsion, WI)|
|Assignee:||Mycogen Plant Science, Inc. (San Diego, CA)|
|Patent Claims:||1. A method for selective heat shock induced enhancement of the constitutive expression of a structural gene in a plant cell comprising the steps of:
(a) transforming said plant cell with a DNA construct comprising an approximately 2 kb plant ubiquitin regulatory region operably joined to a DNA sequence of interest, wherein said plant ubiquitin regulatory region is from a plant ubiquitin gene and comprises at least one heat shock element, a promoter, a transcription start site, and an intron; and
(b) selectively applying stress conditions of high temperature to said transformed plant cell thereby inducing enhancement in expression of said DNA sequence of interest.
2. A method as in claim 1 wherein said regulatory region comprises two heat shock elements.
3. A method as in claim 2 wherein said heat shock elements are situated so that the elements overlap.
4. A method as in claim 1 wherein said intron is approximately 1 kb in length.
5. A method as in claim 1 wherein said plant ubiquitin regulatory region is from a maize ubiquitin gene.
6. A method as in claim 1 wherein said plant cell is a monocot plant cell.
7. A method as in claim 1 wherein said plant cell is a dicot plant cell.
8. A method as in claim 6 wherein said monocot plant is oat.
9. A method as in claim 7 wherein said dicot plant is tobacco.
10. A method as in claim 1 wherein said DNA sequence of interest encodes a structural protein.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||001||1986-06-04||Start Trial||Mycogen Plant Science, Inc. (San Diego, CA)||2039-02-26||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||002||1986-06-04||Start Trial||Mycogen Plant Science, Inc. (San Diego, CA)||2039-02-26||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||003||1986-06-04||Start Trial||Mycogen Plant Science, Inc. (San Diego, CA)||2039-02-26||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|United States of America||5510474||Start Trial|
|United States of America||6020190||Start Trial|
|United States of America||6054574||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.